PHAT
Phathom Pharmaceuticals, Inc.
$10.37
+0.97%
$827.1M
No data for this timeframe.
Vol
Market Cap$827.1M
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (88%)
Inst. Holders50 funds
Inst. Value$300.1M
Inst. Activity12 buys / 6 sells
SEC Reports3
Press Releases2
Recent Activity
Jun 2, 2026
short_volume
Short Volume: PHAT — 65.7% short (0.5M / 0.7M)
Short: 477,531 | Exempt: 328 | TRF Vol: 726,501 | Short Ratio: 65.7% | Off-exchange volume (dark poo
May 22, 2026
Insider
Parikh Asit gifted 28,000 shares
Director
May 20, 2026
Press
Phathom Pharmaceuticals announced the presentation of 31 vonoprazan-related abstracts at DDW 2026, including a Phathom-s
Impact 3/10
May 20, 2026
Insider
Parikh Asit acquired via exercise 17,500 shares
Director @ $4.95 ($86.6K)
May 20, 2026
Insider
Parikh Asit disposed of 17,500 shares
Director
May 1, 2026
Press
Phathom Pharmaceuticals announced its participation in the Digestive Disease Week (DDW) 2026 annual meeting, including a
Impact 1/10
Apr 30, 2026
SEC
Phathom reported Q1 2026 revenue of $58.3M (+104% YoY), beating the $56.8M consensus, but GAAP EPS of -$0.37 missed the
PRESS-RELEASE — Impact 5/10
Apr 7, 2026
SEC
Analysis based on filing metadata only — document content was unavailable
DEFA14A — Impact 3/10
Price Targets
$23.70
+128.5% upside
Strong Buy
Current $10.37
Low $13.00
Median $25.50
High $29.00
10 analysts
$13.00
$29.00
Analyst Ratings
6Strong Buy
9Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Mar 27, 2026 | Barclays | UPGRADE | Equal-Weight → Overweight |
| Feb 27, 2026 | Guggenheim | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.10 ▼ -21.8% | $-0.14 — $-0.06 | 88% YoY | 3 |
| Next Q | $0.05 ▼ -13.5% | $0.02 — $0.11 | 133% YoY | 3 |
| Current FY | $-0.04 ▼ -445.1% | $-0.13 — $0.09 | 98% YoY | 3 |
| Next FY | $1.44 ▼ -6.8% | $1.17 — $1.92 | 3370% YoY | 3 |
Latest Reports
NEUTRAL
Press
3/10
Phathom Pharmaceuticals announced the presentation of 31 vonoprazan-related abstracts at DDW 2026, including a Phathom-s
May 20, 2026
MIXED
PRESS-RELEASE
5/10
Phathom reported Q1 2026 revenue of $58.3M (+104% YoY), beating the $56.8M consensus, but GAAP EPS of -$0.37 missed the
Apr 30, 2026
NEUTRAL
DEFA14A
3/10
Analysis based on filing metadata only — document content was unavailable
Apr 7, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| Invesco Ltd. | $48.0M | — |
| BlackRock, Inc. | $45.1M | — |
| Carlyle Group Inc. | $38.8M | — |
| VANGUARD CAPITAL MANAGEMENT LLC | $28.7M | — |
| STATE STREET CORP | $15.4M | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 22, 2026 | Parikh Asit | G | $0.00 |
| May 20, 2026 | Parikh Asit | M | $86.6K |
| May 20, 2026 | Parikh Asit | D | $0.00 |
| May 19, 2026 | Parikh Asit | A | $0.00 |
| May 19, 2026 | KARBE FRANK | A | $0.00 |
50 institutional holders with $300.1M total value (26,989,821 shares) as of 2026-Q1. Top holders: Invesco, BlackRock,, Carlyle. Net buying activity: 12 institutions added/increased vs 6 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | Invesco Ltd. | 4,322,060 | $48.0M | 16.0% | — |
| 2 | BlackRock, Inc. | 4,061,996 | $45.1M | 15.0% | — |
| 3 | Carlyle Group Inc. | 3,496,808 | $38.8M | 12.9% | — |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 2,583,636 | $28.7M | 9.6% | — |
| 5 | STATE STREET CORP | 1,386,890 | $15.4M | 5.1% | — |
| 6 | WASATCH ADVISORS LP | 1,340,916 | $14.9M | 5.0% | — |
| 7 | NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | 1,205,369 | $13.4M | 4.5% | NEW |
| 8 | FRANKLIN RESOURCES INC | 994,504 | $11.0M | 3.7% | NEW |
| 9 | MARSHALL WACE, LLP | 860,692 | $9.6M | 3.2% | — |
| 10 | VANGUARD PORTFOLIO MANAGEMENT LLC | 666,029 | $7.4M | 2.5% | — |
| 11 | GOLDMAN SACHS GROUP INC | 626,196 | $7.0M | 2.3% | — |
| 12 | CITADEL ADVISORS LLC | 515,900 | $5.7M | 1.9% | — |
| 13 | TWO SIGMA INVESTMENTS, LP | 482,136 | $5.4M | 1.8% | — |
| 14 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 409,015 | $4.5M | 1.5% | — |
| 15 | CITADEL ADVISORS LLC | 383,058 | $4.3M | 1.4% | — |
| 16 | Woodline Partners LP | 369,052 | $4.1M | 1.4% | ADD +97.0% |
| 17 | VANGUARD FIDUCIARY TRUST CO | 338,713 | $3.8M | 1.3% | — |
| 18 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 323,800 | $3.6M | 1.2% | — |
| 19 | RENAISSANCE TECHNOLOGIES LLC | 305,800 | $3.4M | 1.1% | — |
| 20 | Trexquant Investment LP | 293,305 | $3.3M | 1.1% | DOUBLED +114.4% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | NEW | — | 1,205,369 | — | $13.4M | 2026-Q1 |
| FRANKLIN RESOURCES INC | NEW | — | 994,504 | — | $11.0M | 2026-Q1 |
| Woodline Partners LP | ADD | 187,291 | 369,052 | +97.0% | $4.1M | 2026-Q1 |
| Trexquant Investment LP | DOUBLED | 136,824 | 293,305 | +114.4% | $3.3M | 2026-Q1 |
| AMERIPRISE FINANCIAL INC | ADD | 185,744 | 254,219 | +36.9% | $2.8M | 2026-Q1 |
| BALYASNY ASSET MANAGEMENT L.P. | TRIM | 207,085 | 95,301 | -54.0% | $1.1M | 2026-Q1 |
| Brevan Howard Capital Management LP | TRIM | 276,989 | 94,638 | -65.8% | $1.1M | 2026-Q1 |
| Russell Investments Group, Ltd. | DOUBLED | 6,644 | 85,683 | +1189.6% | $951.9K | 2026-Q1 |
| MORGAN STANLEY | TRIM | 117,781 | 76,681 | -34.9% | $851.9K | 2026-Q1 |
| STATE OF WISCONSIN INVESTMENT BOARD | DOUBLED | 15,285 | 44,004 | +187.9% | $488.9K | 2026-Q1 |
| TUDOR INVESTMENT CORP ET AL | ADD | 28,554 | 38,225 | +33.9% | $424.7K | 2026-Q1 |
| LOS ANGELES CAPITAL MANAGEMENT LLC | TRIM | 33,425 | 24,676 | -26.2% | $274.1K | 2026-Q1 |
| GROUP ONE TRADING LLC | NEAR_EXIT | 103,684 | 16,939 | -83.7% | $188.2K | 2026-Q1 |
| ExodusPoint Capital Management, LP | TRIM | 22,401 | 13,293 | -40.7% | $147.7K | 2026-Q1 |
| Rockefeller Capital Management L.P. | DOUBLED | 155 | 4,095 | +2541.9% | $45.5K | 2026-Q1 |
| NISA INVESTMENT ADVISORS, LLC | DOUBLED | 568 | 2,288 | +302.8% | $25.4K | 2026-Q1 |
| BNP Paribas Asset Management Holding S.A. | ADD | 604 | 889 | +47.2% | $9.9K | 2026-Q1 |
| PRICE T ROWE ASSOCIATES INC /MD/ | ADD | 37,071 | 52,453 | +41.5% | $583.00 | 2026-Q1 |
| Brevan Howard Capital Management LP | DOUBLED | 58,097 | 276,989 | +376.8% | $4.6M | 2025-Q4 |
| BALYASNY ASSET MANAGEMENT L.P. | TRIM | 295,161 | 207,085 | -29.8% | $3.4M | 2025-Q4 |
| AMERIPRISE FINANCIAL INC | TRIM | 554,590 | 185,744 | -66.5% | $3.1M | 2025-Q4 |
| Trexquant Investment LP | ADD | 78,183 | 136,824 | +75.0% | $2.3M | 2025-Q4 |
| MORGAN STANLEY | TRIM | 255,573 | 117,781 | -53.9% | $2.0M | 2025-Q4 |
| GROUP ONE TRADING LLC | DOUBLED | 4,248 | 103,684 | +2340.8% | $1.7M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 53,648 | 68,016 | +26.8% | $1.1M | 2025-Q4 |
10 unique insiders with 16 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 22, 2026 | Parikh Asit | Director | GIFT | 28,000 | — | — |
| May 20, 2026 | Parikh Asit | Director | EXERCISE | 17,500 | $4.95 | $86.6K |
| May 20, 2026 | Parikh Asit | Director | D | 17,500 | — | — |
| May 19, 2026 | Parikh Asit | Director | AWARD | 24,122 | — | — |
| May 19, 2026 | KARBE FRANK | Director | AWARD | 24,122 | — | — |
| May 19, 2026 | Schroeder Theodore R | Director | AWARD | 24,122 | — | — |
| May 19, 2026 | COLA MICHAEL F | Director | AWARD | 24,122 | — | — |
| May 19, 2026 | Topper James N | Director | AWARD | 24,122 | — | — |
| May 19, 2026 | Stenhouse Mark | Director | AWARD | 24,122 | — | — |
| May 19, 2026 | FIELDS HEIDI | Director | AWARD | 24,122 | — | — |
| Mar 10, 2026 | Parikh Asit | Director | GIFT | 40,000 | — | — |
| Feb 27, 2026 | Breedlove Robert Charles | Principal Accounting Officer | AWARD | 13,000 | — | — |
| Feb 10, 2026 | Cook Anne Marie | Chief Legal Off. & Corp. Sec. | TAX W/H | 1,535 | $12.82 | $19.7K |
| Feb 10, 2026 | Cook Anne Marie | Chief Legal Off. & Corp. Sec. | AWARD | 3,461 | — | — |
| Feb 10, 2026 | Basta Steven L | President and CEO | TAX W/H | 6,277 | $12.82 | $80.5K |
| Feb 10, 2026 | Basta Steven L | President and CEO | AWARD | 12,362 | — | — |
3 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 1 mixed, 1 neutral. Avg impact: 5.3/10.
MIXED
PRESS-RELEASE
5/10
Phathom reported Q1 2026 revenue of $58.3M (+104% YoY), beating the $56.8M consensus, but GAAP EPS o
Apr 30, 2026
NEUTRAL
DEFA14A
3/10
Analysis based on filing metadata only — document content was unavailable
Apr 7, 2026
BULLISH
8-K
8/10
Phathom Pharmaceuticals reported strong financial results for Q4 and full year 2025, with revenue of
Feb 26, 2026
Current analyst consensus: Strong Buy (88% buy). Based on 17 analysts: 6 strong buy, 9 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$23.70 mean target
+128.5% upside
Strong Buy (1.40)
$13.00 Low
$29.00 High
| Metric | Value |
|---|---|
| Current Price | $10.37 |
| Target Low | $13.00 |
| Target Mean | $23.70 |
| Target Median | $25.50 |
| Target High | $29.00 |
| # Analysts | 10 |
| Recommendation | Strong Buy (1.40) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.10 | $-0.14 | $-0.06 | 87.8% | -21.8% | 0↑ 3↓ | $0.1B | 87.3% | 3 |
| Next Q 2026-09-30 |
$0.05 | $0.02 | $0.11 | 132.9% | -13.5% | 1↑ 1↓ | $0.1B | 88.1% | 3 |
| Current FY 2026-12-31 |
$-0.04 | $-0.13 | $0.09 | 97.9% | -445.1% | 1↑ 1↓ | $0.3B | 90.8% | 3 |
| Next FY 2027-12-31 |
$1.44 | $1.17 | $1.92 | 3370.5% | -6.8% | 1↑ 2↓ | $0.5B | 61.6% | 3 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.097 | |
| 7d ago | $-0.089 | -0.008 |
| 30d ago | $-0.079 | -0.017 |
| 60d ago | $-0.075 | -0.022 |
| 90d ago | $-0.153 | +0.057 |
2 analyst firms have rated this stock: 1 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Mar 27, 2026 | Barclays | UPGRADE | Equal-Weight | Overweight |
| Feb 27, 2026 | Guggenheim | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 6 | 9 | 2 | 0 | 0 | 88% | |
| May 1, 2026 | 6 | 9 | 2 | 0 | 0 | 88% | |
| Apr 1, 2026 | 6 | 9 | 2 | 0 | 0 | 88% | |
| Mar 1, 2026 | 6 | 8 | 3 | 0 | 0 | 82% | |
| Feb 1, 2026 | 6 | 8 | 3 | 0 | 0 | 82% | |
| Jan 1, 2026 | 6 | 8 | 2 | 0 | 0 | 88% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 2, 2026
short_volume
Short Volume: PHAT — 65.7% short (0.5M / 0.7M)
Short: 477,531 | Exempt: 328 | TRF Vol: 726,501 | Short Ratio: 65.7% | Off-exchange volume (dark pool + OTC)
Jun 1, 2026
short_volume
Short Volume: PHAT — 55.3% short (0.3M / 0.6M)
Short: 344,018 | Exempt: 0 | TRF Vol: 622,486 | Short Ratio: 55.3% | Off-exchange volume (dark pool + OTC)
May 22, 2026
other
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
<p>FLORHAM PARK, N.J., May 22, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commerc
May 20, 2026
fda
Phathom Pharmaceuticals Highlights Breadth of Independent Vonoprazan Research at Digestive Disease Week 2026 Annual Meeting
<p>FLORHAM PARK, N.J., May 20, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commerc
May 18, 2026
short_volume
Short Volume: PHAT — 68.5% short (0.4M / 0.5M)
Short: 361,353 | Exempt: 0 | TRF Vol: 527,201 | Short Ratio: 68.5% | Off-exchange volume (dark pool + OTC)
May 13, 2026
short_interest
FTD: PHAT — 67,069 shares ($0.8M) failed to deliver
Settlement: 20260513, Price: $12.53, FTD Value: $840,374.57, PHATHOM PHARMACEUTICALS INC CO
May 5, 2026
short_interest
FTD: PHAT — 61,091 shares ($0.8M) failed to deliver
Settlement: 20260505, Price: $12.87, FTD Value: $786,241.17, PHATHOM PHARMACEUTICALS INC CO
May 4, 2026
short_volume
Short Volume: PHAT — 62.6% short (0.5M / 0.7M)
Short: 451,661 | Exempt: 1,889 | TRF Vol: 721,165 | Short Ratio: 62.6% | Off-exchange volume (dark pool + OTC)
May 1, 2026
fda
Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at DDW 2026 Annual Meeting
<p>FLORHAM PARK, N.J., May 01, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commerc
May 1, 2026
short_interest
FTD: PHAT — 52,026 shares ($0.6M) failed to deliver
Settlement: 20260501, Price: $11.20, FTD Value: $582,691.2, PHATHOM PHARMACEUTICALS INC CO
Apr 30, 2026
earnings
Phathom Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
<p>FLORHAM PARK, N.J., April 30, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on comme
Apr 30, 2026
short_interest
FTD: PHAT — 92,995 shares ($1.1M) failed to deliver
Settlement: 20260430, Price: $11.78, FTD Value: $1,095,481.1, PHATHOM PHARMACEUTICALS INC CO
Apr 30, 2026
earnings_calendar
PHAT Q1 2026 Earnings Scheduled — 2026-04-30
Apr 30, 2026
short_volume
Short Volume: PHAT — 72.1% short (1.3M / 1.8M)
Short: 1,299,370 | Exempt: 39,507 | TRF Vol: 1,801,834 | Short Ratio: 72.1% | Off-exchange volume (dark pool + OTC)
Apr 29, 2026
short_volume
Short Volume: PHAT — 69.1% short (1.0M / 1.4M)
Short: 968,234 | Exempt: 0 | TRF Vol: 1,400,246 | Short Ratio: 69.1% | Off-exchange volume (dark pool + OTC)
Feb 24, 2026
Clinical Trial
Banxiaxiexin Decoction Combined With Vonoprazan-Amoxicillin Dual Therapy in H. Pylori Eradication
Phase Phase 3 — COMPLETED